• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug utilization review of cholinesterase inhibitors in Quebec.

作者信息

Massoud Fadi, Dorais Marc, Charbonneau Claudie, Lescrauwaet Bénédicte, Boucher Jean-Marc, LeLorier Jacques

出版信息

Can J Neurol Sci. 2008 Sep;35(4):508-9. doi: 10.1017/s0317167100009215.

DOI:10.1017/s0317167100009215
PMID:18973072
Abstract
摘要

相似文献

1
Drug utilization review of cholinesterase inhibitors in Quebec.
Can J Neurol Sci. 2008 Sep;35(4):508-9. doi: 10.1017/s0317167100009215.
2
Risk of pneumonia in new users of cholinesterase inhibitors for dementia.痴呆症胆碱酯酶抑制剂新使用者患肺炎的风险。
J Am Geriatr Soc. 2015 May;63(5):869-76. doi: 10.1111/jgs.13380. Epub 2015 Apr 27.
3
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.胆碱酯酶抑制剂治疗痴呆症的耐受性和安全性。
Int J Clin Pract Suppl. 2002 Jun(127):45-63.
4
[Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].[阿尔茨海默病型痴呆症患者使用胆碱酯酶抑制剂的持续用药模式：多奈哌齐、卡巴拉汀和加兰他敏的回顾性比较分析]
Rev Neurol. 2004;39(4):312-6.
5
Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.养老院环境中胆碱酯酶抑制剂的使用模式：一项回顾性分析。
Am J Geriatr Pharmacother. 2006 Jun;4(2):154-60. doi: 10.1016/j.amjopharm.2006.06.002.
6
[Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].[对接受多奈哌齐、卡巴拉汀、加兰他敏和美金刚治疗的西班牙阿尔茨海默病患者抗痴呆药物持续治疗模式的回顾性比较分析]
Rev Neurol. 2006;43(8):449-53.
7
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.胆碱酯酶抑制剂对阿尔茨海默病痴呆的行为和心理症状管理有效吗？对多奈哌齐、卡巴拉汀和加兰他敏随机、安慰剂对照试验的系统评价。
Int Psychogeriatr. 2009 Oct;21(5):813-24. doi: 10.1017/S1041610209990354. Epub 2009 Jun 19.
8
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.当前特定治疗方法对阿尔茨海默病患者行为和心理症状的影响差异：一项 12 个月、随机、开放标签试验。
J Alzheimers Dis. 2014;39(3):477-85. doi: 10.3233/JAD-131190.
9
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.多奈哌齐、卡巴拉汀和加兰他敏对阿尔茨海默病认知、生活质量及不良事件临床疗效的系统评价。
Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. doi: 10.1002/gps.1402.
10
Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.加兰他敏、多奈哌齐和卡巴拉汀这三种乙酰胆碱酯酶抑制剂对SH-SY5Y神经母细胞瘤细胞提供的神经保护作用不均等：烟碱样受体的作用
J Pharmacol Exp Ther. 2005 Dec;315(3):1346-53. doi: 10.1124/jpet.105.090365. Epub 2005 Sep 6.

引用本文的文献

1
Adherence of Anti-Dementia Medications in Alzheimer's Disease and Related Dementia: A Nationwide Cohort Study in Korea.阿尔茨海默病及相关痴呆症中抗痴呆药物的依从性：韩国的一项全国性队列研究
J Korean Med Sci. 2025 Sep 8;40(35):e226. doi: 10.3346/jkms.2025.40.e226.
2
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.胆碱酯酶抑制剂的耐受性：一项基于人群的持续性、依从性和换药情况研究。
Drugs Aging. 2017 Mar;34(3):221-231. doi: 10.1007/s40266-017-0438-x.
3
Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
阿尔茨海默病治疗中依从性和偏好的真实世界评估。
Clin Interv Aging. 2015 Nov 3;10:1779-87. doi: 10.2147/CIA.S85319. eCollection 2015.
4
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.痴呆症药物治疗的持续性和依从性：患者、医疗服务提供者及系统因素的相关性
Can J Psychiatry. 2014 Dec;59(12):624-31. doi: 10.1177/070674371405901203.
5
Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.从卡巴拉汀胶囊到透皮贴剂：阿尔茨海默病和帕金森病痴呆管理的治疗进展
Prim Care Companion CNS Disord. 2014 Sep 4;16(5). doi: 10.4088/PCC.14r01654. eCollection 2014.
6
Update on the pharmacological treatment of Alzheimer's disease.阿尔茨海默病的药物治疗进展。
Curr Neuropharmacol. 2010 Mar;8(1):69-80. doi: 10.2174/157015910790909520.
7
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.停用胆碱酯酶抑制剂治疗及其在荷兰的决定因素：一项回顾性队列研究。
Drugs Aging. 2010 Aug 1;27(8):663-75. doi: 10.2165/11538230-000000000-00000.
8
Care of dementia in Canada: a collaborative care approach with a central role for the primary care physician.加拿大的痴呆症护理：一种以初级保健医生为核心角色的协作式护理方法。
J Nutr Health Aging. 2010 Feb;14(2):105-6. doi: 10.1007/s12603-010-0020-2.